Please use this identifier to cite or link to this item:
Type: Artigo
Title: Safety Of Switching From Natalizumab Straight Into Fingolimod In A Group Of Jcv-positive Patients With Multiple Sclerosis
Title Alternative: Segurança Na Mudança Direta De Natalizumabe Para Fingolimode Em Um Grupo De Pacientes Com Esclerose Múltipla E Positivos Para Jcv
Author: Fragoso Y.D.
Alves-Leon S.V.
Becker J.
Brooks J.B.B.
Correa E.C.
Damasceno A.
da Gama P.D.
da Gama R.A.
Matta A.P.C.
Maciel E.P.
Winckler T.C.D.
Abstract: To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods: Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results: After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion: Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching. © 2016, Associacao Arquivos de Neuro-Psiquiatria. All Rights Reserved.
Subject: Fingolimod Hydrochloride
Multiple Sclerosis
Editor: Associacao Arquivos de Neuro-Psiquiatria
Citation: Arquivos De Neuro-psiquiatria. Associacao Arquivos De Neuro-psiquiatria, v. 74, n. 8, p. 650 - 652, 2016.
Rights: aberto
Identifier DOI: 10.1590/0004-282X20160090
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
2-s2.0-84983315310.pdf85.71 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.